Select a community
Mood Conditions including Depression, Anxiety, Bipolar, OCD, and PTSD
Find out more about the PatientsLikeMe
Mood Conditions Community
Home > Community Treatment Reports > Desvenlafaxine Treatment Report
What is Desvenlafaxine?

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is an extended release formulation believed to treat depression by affecting the levels of serotonin and norepinephrine, two neurotransmitters associated with depression.

Side Effects

Side effects as an overall problem

Severe
6 24%
Moderate
3 12%
Mild
10 40%
None
6 24%

Most commonly reported side effects

Sedation
8 32%
Random Tiredness/Energy
6 24%
nausea, dizziness
4 16%
Sluggishness
4 16%
Depression
4 16%
Abnormal dreams
3 12%
  • Mild
  • Moderate
  • Severe

Dosages

  1 mg daily 2 mg daily 20 mg daily 50 g daily 50 mg daily 100 mg daily 150 mg daily 200 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 55 Number of Patients: 55 17 Number of Patients: 17 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Desvenlafaxine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
11 55% Did not seem to work: 55%
Side effects too severe
8 40% Side effects too severe: 40%
Other
4 20% Other: 20%
Doctor's advice
3 15% Doctor's advice: 15%
Personal research
1 5% Personal research: 5%

See all 20 patients who’ve stopped taking Desvenlafaxine

Currently Taking Desvenlafaxine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
6
15
24
9
0

Stopped Taking Desvenlafaxine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
10
7
2
1
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
24 96%
Usually
1 4%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
3 12%
Somewhat
1 4%
A little
4 16%
Not at all
17 68%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
2 8%
$25-49
4 16%
< $25
10 40%

Report created on November 22, 2009.